Michel Azizi

List of Publications by Year in descending order

107 papers	16,359 citations	66343 42 h-index	27406 106 g-index
116 all docs	116 docs citations	116 times ranked	17061 citing authors

#	Article	IF	Citations
1	2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal, 2018, 39, 3021-3104.	2.2	6,826
2	2018 ESC/ESH Guidelines for the management of arterial hypertension. Journal of Hypertension, 2018, 36, 1953-2041.	0.5	2,129
3	2018 Practice Guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. Journal of Hypertension, 2018, 36, 2284-2309.	0.5	689
4	Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet, The, 2018, 391, 2335-2345.	13.7	526
5	Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet, The, 2015, 385, 1957-1965.	13.7	453
6	Hypertension, the reninâ€“angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19. Cardiovascular Research, 2020, 116, 1688-1699.	3.8	282
7	2018 Practice guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. Blood Pressure, 2018, 27, 314-340.	1.5	254
8	Pharmacologic Demonstration of the Synergistic Effects of a Combination of the Renin Inhibitor Aliskiren and the AT1 Receptor Antagonist Valsartan on the Angiotensin IIâ€“Renin Feedback Interruption. Journal of the American Society of Nephrology: JASN, 2004, 15, 3126-3133.	6.1	234
9	First International Consensus on the diagnosis and management of fibromuscular dysplasia. Vascular Medicine, 2019, 24, 164-189.	1.5	232
10	Renin inhibition with aliskiren: where are we now, and where are we going?. Journal of Hypertension, 2006, 24, 243-256.	0.5	229
11	Aliskiren, an Orally Effective Renin Inhibitor, Provides Antihypertensive Efficacy Alone and in Combination With Valsartan. American Journal of Hypertension, 2007, 20, 11-20.	2.0	215
12	Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	13.7	197
13	Combined Blockade of the Renin-Angiotensin System With Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Type 1 Receptor Antagonists. Circulation, 2004, 109, 2492-2499.	1.6	184
14	Additive Effects of Combined Angiotensin-Converting Enzyme Inhibition and Angiotensin II Antagonism on Blood Pressure and Renin Release in Sodium-Depleted Normotensives. Circulation, 1995, 92, 825-834.	1.6	183
15	Home Blood-Pressure Monitoring in Patients Receiving Sunitinib. New England Journal of Medicine, 2008, 358, 95-97.	27.0	181
16	European consensus on the diagnosis and management of fibromuscular dysplasia. Journal of Hypertension, 2014, 32, 1367-1378.	0.5	154
17	The double challenge of resistant hypertension and chronic kidney disease. Lancet, The, 2015, 386, 1588-1598.	13.7	147
18	Evaluation of Adherence Should Become an Integral Part of Assessment of Patients With Apparently Treatment-Resistant Hypertension. Hypertension, 2016, 68, 297-306.	2.7	147

#	Article	IF	Citations
19	PHACTR1 Is a Genetic Susceptibility Locus for Fibromuscular Dysplasia Supporting Its Complex Genetic Pattern of Inheritance. PLoS Genetics, 2016, 12, e1006367.	3.5	146
20	Adherence to Antihypertensive Treatment and the Blood Pressureâ€“Lowering Effects of Renal Denervation in the Renal Denervation for Hypertension (DENERHTN) Trial. Circulation, 2016, 134, 847-857.	1.6	144
21	Reciprocal Regulation of Plasma Apelin and Vasopressin by Osmotic Stimuli. Journal of the American Society of Nephrology: JASN, 2008, 19, 1015-1024.	6.1	121
22	High Prevalence of Multiple Arterial Bed Lesions in Patients With Fibromuscular Dysplasia. Hypertension, 2017, 70, 652-658.	2.7	115
23	Sequential nephron blockade versus sequential reninâ€“angiotensin system blockade in resistant hypertension. Journal of Hypertension, 2012, 30, 1656-1664.	0.5	111
24	Association Between 2 Angiographic Subtypes of Renal Artery Fibromuscular Dysplasia and Clinical Characteristics. Circulation, 2012, 126, 3062-3069.	1.6	110
25	Additive Effects of Losartan and Enalapril on Blood Pressure and Plasma Active Renin. Hypertension, 1997, 29, 634-640.	2.7	99
26	Six-Month Results of Treatment-Blinded Medication Titration for Hypertension Control After Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in the RADIANCE-HTN SOLO Trial. Circulation, 2019, 139, 2542-2553.	1.6	97
27	Drug adherence in hypertension. Journal of Hypertension, 2017, 35, 1133-1144.	0.5	79
28	Device-based therapies for arterial hypertension. Nature Reviews Cardiology, 2020, 17, 614-628.	13.7	77
29	Pilot study of combined blockade of the reninâ€“angiotensin system in essential hypertensive patients. Journal of Hypertension, 2000, 18, 1139-1147.	0.5	67
30	Meta-analysis of randomized controlled trials of renal denervation in treatment-resistant hypertension. Blood Pressure, 2015, 24, 263-274.	1.5	65
31	SPARTE Study: Normalization of Arterial Stiffness and Cardiovascular Events in Patients With Hypertension at Medium to Very High Risk. Hypertension, 2021, 78, 983-995.	2.7	65
32	A multinational clinical approach to assessing the effectiveness of catheter-based ultrasound renal denervation: The RADIANCE-HTN and REQUIRE clinical study designs. American Heart Journal, 2018, 195, 115-129.	2.7	64
33	Hormonal and Hemodynamic Effects of Aliskiren and Valsartan and Their Combination in Sodium-Replete Normotensive Individuals. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 947-955.	4.5	57
34	Association of Smoking With Phenotype at Diagnosis and Vascular Interventions in Patients With Renal Artery Fibromuscular Dysplasia. Hypertension, 2013, 61, 1227-1232.	2.7	57
35	Renal denervation with a percutaneous bipolar radiofrequency balloon catheter in patients with resistant hypertension: 6-month results from the REDUCE-HTN clinical study. EuroIntervention, 2015, 10, 1213-1220.	3.2	56
36	Managing cardiovascular and renal risk: the potential of direct renin inhibition. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2009, 10, 65-76.	1.7	53

#	Article	IF	Citations
37	Nonadherence in Hypertension: How to Develop and Implement Chemical Adherence Testing. Hypertension, 2022, 79, 12-23.	2.7	51
38	12-Month Results From the Unblinded Phase of the RADIANCE-HTN SOLO Trial of Ultrasound Renal Denervation. JACC: Cardiovascular Interventions, 2020, 13, 2922-2933.	2.9	47
39	Emerging Drug Classes and Their Potential Use in Hypertension. Hypertension, 2019, 74, 1075-1083.	2.7	46
40	European Society of Hypertension position paper on renal denervation 2018. Journal of Hypertension, 2018, 36, 2042-2048.	0.5	39
41	Integrating Drug Pharmacokinetics for Phenotyping Individual Renin Response to Angiotensin II Blockade in Humans. Hypertension, 2004, 43, 785-790.	2.7	38
42	Conformational changes in prorenin during renin inhibition in vitro and in vivo. Journal of Hypertension, 2006, 24, 529-534.	0.5	37
43	Twenty-Four-Hour Blood Pressure Monitoring to Predict and Assess Impact of Renal Denervation. Hypertension, 2017, 69, 494-500.	2.7	34
44	Genetic investigation of fibromuscular dysplasia identifies risk loci and shared genetics with common cardiovascular diseases. Nature Communications, 2021, 12, 6031.	12.8	34
45	The difficult conception, birth and delivery of a renin inhibitor: controversies around aliskiren. Journal of Hypertension, 2007, 25, 1775-1782.	0.5	32
46	Renal Denervation for Treatment of Hypertension: a Second Start and New Challenges. Current Hypertension Reports, 2016, 18, 6.	3.5	32
47	Cause of renal infarction. Journal of Hypertension, 2018, 36, 634-640.	0.5	31
48	True antihypertensive efficacy of sequential nephron blockade in patients with resistant hypertension and confirmed medication adherence. Journal of Hypertension, 2015, 33, 2526-2533.	0.5	28
49	Clinical Trial Design Principles and Outcomes Definitions for Device-Based Therapies for Hypertension: A Consensus Document From the Hypertension Academic Research Consortium. Circulation, 2022, 145, 847-863.	1.6	28
50	Design Considerations for Clinical Trials of Autonomic Modulation Therapies Targeting Hypertension and Heart Failure. Hypertension, 2015, 65, 5-15.	2.7	27
51	Resistant Hypertension and Atherosclerotic Renal Artery Stenosis. Hypertension, 2019, 74, 1516-1523.	2.7	27
52	Haemodynamic effects of dual blockade of the renin???angiotensin system in spontaneously hypertensive rats. Journal of Hypertension, 2004, 22, 619-627.	0.5	26
53	Renal artery stenosis following renal denervation. Journal of Hypertension, 2014, 32, 2101-2105.	0.5	26
54	Abdominal Aortic Calcifications Influences the Systemic and Renal Hemodynamic Response to Renal Denervation in the DENERHTN (Renal Denervation for Hypertension) Trial. Journal of the American Heart Association, 2017, 6, .	3.7	25

#	Article	IF	Citations
55	Renin Inhibitors and Cardiovascular and Renal Protection: An Endless Quest?. Cardiovascular Drugs and Therapy, 2013, 27, 145-153.	2.6	24
56	Aldosterone-Related Myocardial Extracellular Matrix Expansion in Hypertension in Humans. JACC: Cardiovascular Imaging, 2020, 13, 2149-2159.	5.3	23
57	Renin inhibition. Current Opinion in Nephrology and Hypertension, 2006, 15, 505-510.	2.0	21
58	Physiologic Consequences of Vasopeptidase Inhibition in Humans: Effect of Sodium Intake. Journal of the American Society of Nephrology: JASN, 2002, 13, 2454-2463.	6.1	20
59	Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor AVE7688 in humans. Clinical Pharmacology and Therapeutics, 2006, 79, 49-61.	4.7	20
60	Salvage Therapy with Bevacizumabâ€“Sunitinib Combination after Failure of Sunitinib Alone for Metastatic Renal Cell Carcinoma: A Case Series. European Urology, 2009, 56, 207-211.	1.9	20
61	Eligibility for Renal Denervation: Anatomical Classification and Results in Essential Resistant Hypertension. CardioVascular and Interventional Radiology, 2015, 38, 79-87.	2.0	20
62	Rare loss-of-function mutations of PTGIR are enriched in fibromuscular dysplasia. Cardiovascular Research, 2021, 117, 1154-1165.	3.8	20
63	Pharmacokinetic-pharmacodynamic interactions of candesartan cilexetil and losartan. Journal of Hypertension, 1999, 17, 561-568.	0.5	19
64	Drug-resistant hypertension in primary aldosteronism patients undergoing adrenal vein sampling: the AVIS-2-RH study. European Journal of Preventive Cardiology, 2022, 29, e85-e93.	1.8	19
65	Direct renin inhibition: clinical pharmacology. Journal of Molecular Medicine, 2008, 86, 647-654.	3.9	18
66	Dual renin???angiotensin system blockade restores blood pressure???renin dependency in individuals with low renin concentrations. Journal of Hypertension, 2003, 21, 1887-1895.	0.5	17
67	RENIN INHIBITION WITH ALISKIREN. Clinical and Experimental Pharmacology and Physiology, 2008, 35, 426-430.	1.9	15
68	Ambulatory Blood Pressure Monitoring to Predict Response to Renal Denervation. Hypertension, 2021, 77, 529-536.	2.7	15
69	Poor adherence to medication and salt restriction as a barrier to reaching blood pressure control in patients with hypertension: Cross-sectional study from 12 sub-Saharan countries. Archives of Cardiovascular Diseases, 2020, 113, 433-442.	1.6	15
70	Greater efficacy of aldosterone blockade and diuretic reinforcement vs. dual reninâ€“angiotensin blockade for left ventricular mass regression in patients with resistant hypertension. Journal of Hypertension, 2014, 32, 2038-2044.	0.5	14
71	Current progress in clinical, molecular, and genetic aspects of adult fibromuscular dysplasia. Cardiovascular Research, 2022, 118, 65-83.	3.8	14
72	Predictors of blood pressure response to ultrasound renal denervation in the RADIANCE-HTN SOLO study. Journal of Human Hypertension, 2022, 36, 629-639.	2.2	14

#	Article	IF	Citations
73	How to perform a cost-effectiveness analysis with surrogate endpoint: renal denervation in patients with resistant hypertension (DENERHTN) trial as an example. Blood Pressure, 2018, 27, 66-72.	1.5	13
74	Usefulness of Magnetic Resonance Imaging in the Diagnosis of Juxtaglomerular Cell Tumors: A Report of 10 Cases and Review of the Literature. American Journal of Kidney Diseases, 2019, 73, 566-571.	1.9	13
75	Beyond Atherosclerosis and Fibromuscular Dysplasia: Rare Causes of Renovascular Hypertension. Hypertension, 2021, 78, 898-911.	2.7	12
76	Rationale for Combining Blockers of the Renin-Angiotensin System. Seminars in Nephrology, 2007, 27, 544-554.	1.6	10
77	Transcriptome Analysis of Human Reninomas as an Approach to Understanding Juxtaglomerular Cell Biology. Hypertension, 2017, 69, 1145-1155.	2.7	10
78	Impaired atrioventricular transport in patients with transposition of the great arteries palliated by atrial switch and preserved systolic right ventricular function: A magnetic resonance imaging study. Congenital Heart Disease, 2017, 12, 458-466.	0.2	10
79	Catheter-based renal denervation for treatment of hypertension. Lancet, The, 2017, 390, 2124-2126.	13.7	10
80	Clinic Versus Ambulatory Blood Pressure in Resistant Hypertension: Impact of Antihypertensive Medication Nonadherence. Hypertension, 2019, 74, 1096-1103.	2.7	10
81	Home blood pressure monitoring and e-Health: investigation of patientsâ€™ experience with the Hy-Result system. Blood Pressure Monitoring, 2020, 25, 155-161.	0.8	9
82	Effect of Contrasted Sodium Diets on the Pharmacokinetics and Pharmacodynamic Effects of Reninâ€“Angiotensin System Blockers. Hypertension, 2013, 61, 1239-1245.	2.7	8
83	Clinical characteristics, antihypertensive medication use and blood pressure control among patients with treatment-resistant hypertension. Journal of Hypertension, 2019, 37, 2216-2224.	0.5	7
84	Aldosterone receptor antagonists. Annales D'Endocrinologie, 2021, 82, 179-181.	1.4	7
85	P-glycoprotein influences urinary excretion of aldosterone in healthy individuals. Journal of Hypertension, 2019, 37, 2225-2231.	0.5	6
86	Plasma renin and aldosterone concentrations related to endovascular ultrasound renal denervation in the RADIANCE-HTN SOLO trial. Journal of Hypertension, 2022, 40, 221-228.	0.5	6
87	Design of renal denervation studies not confounded by antihypertensive drugs. Journal of the American Society of Hypertension, 2015, 9, 337-340.	2.3	5
88	Sequential nephron blockade with combined diuretics improves diastolic function in patients with resistant hypertension. ESC Heart Failure, 2020, 7, 2561-2571.	3.1	5
89	Cardiometabolic Disorders and the Risk of Critical COVID-19 as Compared to Influenza Pneumonia. Journal of Clinical Medicine, 2021, 10, 4618.	2.4	4
90	Use of traditional medicine and control of hypertension in 12 African countries. BMJ Global Health, 2022, 7, e008138.	4.7	4

#	Article	IF	Citations
91	Detecting Nonadherence to Antihypertensive Treatment. Hypertension, 2017, 70, 257-258.	2.7	3
92	Antihypertensive strategies and hypertension control in Sub-Saharan Africa. European Journal of Preventive Cardiology, 2020, 28, e21-e25.	1.8	3
93	Renal Artery Variations in Patients With Mild-to-Moderate Hypertension From the RADIANCE-HTN SOLO Trial. Cardiovascular Revascularization Medicine, 2022, 39, 58-65.	0.8	3
94	Will SPYRAL HTN-ON MED change my practice? SPYRAL HTN-ON MED: a prospective, randomised, sham-controlled trial on renal denervation in the presence of antihypertensive medications. EuroIntervention, 2018, 14, e598-e602.	3.2	3
95	Using social media to recruit study participants for a randomized trial for hypertension. European Heart Journal Digital Health, 2020, 1, 71-74.	1.7	3
96	Renal denervation for resistant hypertension â€“ Authors' reply. Lancet, The, 2015, 386, 1240.	13.7	2
97	Will SPYRAL HTN-OFF MED change my practice? SPYRAL HTN-OFF MED: a prospective, randomised, sham-controlled trial on renal denervation in the absence of antihypertensive medications. EuroIntervention, 2018, 14, e603-e606.	3.2	2
98	Blood pressure-lowering medicines implemented in 12 African countries: the cross-sectional multination EIGHT study. BMJ Open, 2021, 11, e049632.	1.9	2
99	Renin???angiotensin system blockade. Journal of Hypertension, 2004, 22, 459-462.	0.5	1
100	Effets vasculaires et rÃ©naux des mÃ©dicaments anti-angiogÃ©niques : recommandations franÃ§aises pour la pratique. Sang Thrombose Vaisseaux, 2009, 21, 151-166.	0.1	1
101	Renal denervation in hypertension: Towards a true revival?. Archives of Cardiovascular Diseases, 2018, 111, 541-544.	1.6	1
102	Resistant Hypertension. , 2018, , 398-408.		1
103	SAT-012 Urinary Aldosterone Assay Using LC-MS/MS Could Improve Primary Aldosteronism Screening. Journal of the Endocrine Society, 2019, 3, .	0.2	1
104	Highlights from International Congress. High Blood Pressure and Cardiovascular Prevention, 2008, 15, 91-104.	2.2	0
105	Drug-Induced Hypertension. Updates in Hypertension and Cardiovascular Protection, 2020, , 159-166.	0.1	0
106	Drug Adherence in Resistant Hypertension. Updates in Hypertension and Cardiovascular Protection, 2018, , 185-197.	0.1	0
107	La recherche en hypertension artÃ©rielle en France. Bulletin De L'Academie Nationale De Medecine, 2018, 202, 1571-1579.	0.0	0